(2S,3R)-methyl-2-benzamidomethyl-3-hydroxybutyrate → Methyl 2-((benzoylamino)methyl)-3-oxobutanoate
反応式
[CH3:1][O:2][C:3](=[O:18])[C@@H:4]([CH2:8][NH:9][C:10](=[O:17])[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=1)[C@H:5]([OH:7])[CH3:6].COC(=O)[C@H](CNC(=O)C1C=CC=CC=1)[C@H](O)C>>[CH3:1][O:2][C:3](=[O:18])[CH:4]([CH2:8][NH:9][C:10](=[O:17])[C:11]1[CH:12]=[CH:13][CH:14]=[CH:15][CH:16]=1)[C:5](=[O:7])[CH3:6]参加物
3
実験手順
The ADH-LK variant with SEQ ID No. 90 was used for further evolution of an efficient KRED for production of (2S,3R)-methyl-2-benzamidomethyl-3-hydroxybutyrate. Similarly, an ADH-LK variant with SEQ ID No.94 containing 10 mutations compared to ADH-LK which gave primarily the (2R,3R) stereoisomer, was used for further evolution of an efficient KRED for production of (2R,3R)-methyl-2-benzamidomethyl-3-hydroxybutyrate.
後処理
- additionSimilarly, an ADH-LK variant with SEQ ID No.94 containing 10 mutations
- customgave primarily the (2R,3R) stereoisomer